# Phillip Maderia

> Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.

- **Role:** Chief Executive Officer at PranaX
- **Organizations:** PranaX, Lonza (prior), Codiak BioSciences (prior), LFB-USA (prior), Sanofi Genzyme (prior)
- **Nationality:** American
- **Known for:** Built Lonza's first 500L-scale GMP exosome manufacturing process, Ran the Lexington, MA exosome site for Lonza - a facility widely regarded as a reference plant in the sector, As VP of Manufacturing at Codiak, led supply chain for three clinical exosome programs in oncology

## Career timeline

- **1990s-2010s** — Senior manufacturing and engineering leadership roles at Sanofi Genzyme and LFB-USA
- **pre-2021** — Vice President of Manufacturing Operations at Codiak BioSciences, leading supply for three exosome clinical programs in oncology
- **2021** — Joined Lonza as Site Head and Exosome Business Leader of the Lexington, MA facility following Lonza's acquisition of Codiak's manufacturing plant
- **2023** — Instrumental in Lonza's acquisition of Codiak BioSciences' intellectual property and clinical programs
- **2023-2024** — Led construction of Lonza's first 500L-scale GMP exosome manufacturing process; oversaw a $12M exosome operation
- **2026-01** — PranaX closes $17M Series A
- **2025-03** — Appointed Chief Executive Officer of PranaX Corporation

## Achievements

- Built Lonza's first 500L-scale GMP exosome manufacturing process
- Ran the Lexington, MA exosome site for Lonza - a facility widely regarded as a reference plant in the sector
- As VP of Manufacturing at Codiak, led supply chain for three clinical exosome programs in oncology
- Instrumental in Lonza's 2023 acquisition of Codiak BioSciences' IP and clinical assets
- Named CEO of PranaX in March 2025 to commercialize stem cell-derived exosomes

## Latest updates

- **2025-03** — Appointed CEO of PranaX to lead exosome innovation.
- **2026-01** — PranaX closed a $17M Series A round.
- **2025-09** — Represented PranaX as a speaker at an industry event, per his LinkedIn.

## Links

- Website: https://www.pranax.com/
- LinkedIn: https://www.linkedin.com/in/phillip-maderia-270651a

---

Profile page: https://yespress.io/phillip-maderia
Published by YesPress — https://yespress.io
Last updated: 2026-07-08